Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.

[1]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[2]  T. Henry,et al.  Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. , 2015, American heart journal.

[3]  H. Gurm,et al.  Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). , 2015, The American journal of cardiology.

[4]  K. Anstrom,et al.  Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice: The Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome Prospective Open Label Antiplatelet Therapy Study , 2015, Circulation. Cardiovascular interventions.

[5]  L. Boulanger,et al.  Moving branded statins to lowest copay tier improves patient adherence. , 2015, Journal of managed care pharmacy : JMCP.

[6]  A. Jaffe,et al.  A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .

[7]  A. Jaffe,et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[8]  K. Anstrom,et al.  Abstract 16776: Can We Rely on Patients to Report Rehospitalizations After Acute Myocardial Infarction? Implications for the Design of Future Practical Clinical Studies , 2014 .

[9]  E. Peterson,et al.  Persistence of evidence-based medication use after discharge from academic versus nonacademic hospitals among patients with non-ST-segment elevation myocardial infarction. , 2014, The American journal of cardiology.

[10]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[11]  F. Gaita,et al.  Discontinuation of dual antiplatelet therapy over 12 months after acute coronary syndromes increases risk for adverse events in patients treated with percutaneous coronary intervention: systematic review and meta-analysis. , 2014, Journal of interventional cardiology.

[12]  T. Brennan,et al.  Eliminating medication copayments reduces disparities in cardiovascular care. , 2014, Health affairs.

[13]  Eric D. Peterson,et al.  Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry , 2014, Journal of the American Heart Association.

[14]  Braden J. Manns,et al.  Association between Drug Insurance Cost Sharing Strategies and Outcomes in Patients with Chronic Diseases: A Systematic Review , 2014, PloS one.

[15]  R. Haynes,et al.  Interventions for enhancing medication adherence. , 2008, The Cochrane database of systematic reviews.

[16]  T. Brennan,et al.  Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes. , 2014, American heart journal.

[17]  Antonio Colombo,et al.  Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.

[18]  Claire Buckley,et al.  The Effect of Copayments for Prescriptions on Adherence to Prescription Medicines in Publicly Insured Populations; A Systematic Review and Meta-Analysis , 2013, PloS one.

[19]  H. Gurm,et al.  Contemporary Use of Prasugrel in Clinical Practice: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium , 2013, Circulation. Cardiovascular quality and outcomes.

[20]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[21]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[22]  Harlan M Krumholz,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[23]  G. Stone,et al.  Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[24]  T. Brennan,et al.  Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction. , 2012, Health services research.

[25]  Katie Merrell,et al.  In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions. , 2012, Health affairs.

[26]  K. Anstrom,et al.  Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. , 2012, American heart journal.

[27]  Lonny Reisman,et al.  Full coverage for preventive medications after myocardial infarction. , 2011, The New England journal of medicine.

[28]  K. Anstrom,et al.  Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. , 2011, American heart journal.

[29]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[30]  R. F. Kelly,et al.  Association of medical noncompliance and long-term adverse outcomes, after myocardial infarction in a minority and uninsured population. , 2009, Translational research : the journal of laboratory and clinical medicine.

[31]  W. Doucette,et al.  Effect of cost sharing on prescription drug use by Medicare beneficiaries prior to the Medicare Drug Benefit and potential adverse selection in the benefit. , 2009, Journal of the American Pharmacists Association : JAPhA.

[32]  A. Fendrick,et al.  Effects of Increased Patient Cost Sharing on Socioeconomic Disparities in Health Care , 2008, Journal of General Internal Medicine.

[33]  A. Oxman,et al.  Pharmaceutical policies: effects of cap and co-payment on rational drug use. , 2008, The Cochrane database of systematic reviews.

[34]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[35]  Dana P Goldman,et al.  Prescription drug cost sharing: associations with medication and medical utilization and spending and health. , 2007, JAMA.

[36]  J. Gurwitz,et al.  Patients At-Risk for Cost-Related Medication Nonadherence: A Review of the Literature , 2007, Journal of General Internal Medicine.

[37]  D. Ashby,et al.  Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method. , 2006, International journal of epidemiology.

[38]  R. Goetzel,et al.  The effects of prescription drug cost sharing: a review of the evidence. , 2005, The American journal of managed care.

[39]  W C Hsiao,et al.  Results and policy implications of the resource-based relative-value study. , 1988, The New England journal of medicine.

[40]  M. Finkelstein,et al.  Some aspects of the pharmacology of clemizole hydrochloride. , 1960, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.